INTRODUCTION
============

Breast cancer (BC) is often associated with long-term psychological distress, chronic pain, fatigue and impaired quality of life (QoL) [@b1-cln_72p758]-[@b5-cln_72p758]. Approximately 20% to 50% of patients complain about pain, a number which rises to 90% for patients in metastatic or terminal stages [@b6-cln_72p758]-[@b10-cln_72p758].

Pain is one of the most frequently reported adverse effects that occurs as part of the disease process or as a side-effect of treatment. It is a problem for a majority of BC patients and has an unfavorable effect on QoL [@b11-cln_72p758]-[@b15-cln_72p758].

More recent epidemiological data obtained from a meta-analysis suggest that pain is prevalent in 39.3% of cases after curative treatment, 55.0% during cancer treatment, and in 66.4% in advanced or terminal stages of the disease [@b10-cln_72p758].

The frequency of pain increases as the disease progresses, causing physical, emotional, spiritual and functional discomfort. This impedes performance of daily activities and disturbs sleeping and eating habits. As a result, cognitive function is impaired and affective, sexual and family relationships are strained, and work and leisure activities are difficult. This leads to greatly decreased QoL for these women [@b9-cln_72p758].

Pain is understood as a complex multidimensional experience that must be evaluated in its affective and cognitive dimension. Emotional and cognitive factors have a strong influence on pain perception [@b16-cln_72p758]-[@b18-cln_72p758]; however, untreated pain affects physical, psychological, social and spiritual well-being [@b19-cln_72p758],[@b20-cln_72p758].

Pain is a stressful, individual and subjective human experience and has been associated with feelings of social isolation [@b21-cln_72p758]; thus, evaluating pain is one of the most challenging areas of care for this type of patient. The ability to accurately measure and interpret pain through valid and reliable tools or instruments may be clinically important in determining medical protocol and non-pharmaceutical interventions [@b22-cln_72p758].

The purpose of this study was to evaluate the influence of pain on the QoL of women with BC. A detailed evaluation of pain enables caretakers to create a strategy to reduce pain and prevent any secondary symptoms, which improves patient QoL.

MATERIALS AND METHODS
=====================

This prospective study was conducted with 400 women diagnosed with BC undergoing chemotherapy, radiotherapy, surgery, hormone therapy, or exclusively in palliative care. The study occurred in the oncology center at a referral hospital in a medium-sized city in the northeast of Brazil from July 2014 to April 2015. Patients were selected through non-probability sampling, and patient interviews were conducted during appointments or in the chemotherapy infusion room.

A patient was considered eligible for the study if they were diagnosed with BC, undergoing treatment for the disease or exclusively in palliative care, and were over 18. Women without cognitive ability and/or verbalization, patients who had not started treatment, and those who had been previously diagnosed with depression were excluded.

Three study groups were created within the sample: 1-118 patients without metastasis (MTX), 2- 160 patients with loco-regional MTX and 3- 122 patients with distant MTX.

Ethical issues were considered, and the Local Research Ethics Committee approved the present study (n°. CAAE 17956113.9.0000.5293) in compliance with the Declaration of Helsinki and Resolution 466/12 of the Brazilian National Health Council, which addresses research on human beings. Before starting the interview, the study objectives were explained, and the patients participating in the study were asked to sign a free and informed consent form. This ensured that participation was voluntary and that answers would be kept anonymous and confidential.

Pain was evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ) proposed by Melzack [@b23-cln_72p758] and validated in Portuguese by Ferreira et al. [@b24-cln_72p758]. This version consists of 15 pain descriptors belonging to its three dimensions: Sensory (throbbing, jumping, flashing, sharp-pricking, tugging, burning, spreading, sore/aching), Affective (tiring-exhausting, sickening, suffocating, frightful-blinding, nagging) and Evaluative (troublesome, unbearable).

These descriptors were classified as "present" or "absent." In addition to these descriptors, the instrument also integrates a Numeric Pain Rating Scale. The level of pain intensity was classified as mild, moderate and severe. These levels were based on the intensity with which each patient classified their pain on the Numerical Scale. Thus, 1 to 3 represents mild pain, whereas 4 to 6 represents moderate pain and 7 to 10 intense pain. The questionnaire also includes a Body Diagram to determine the location of the pain referred to by the subjects.

To assess QoL, the European Organization device for Research and Treatment for Cancer Questionnaire-Core 30 (EORTC QLQ-C30) was used. This questionnaire is a valid and reliable evaluation of cancer patient QoL and has been considered useful in many clinical trials and studies. The EORTC QLQ-C30 (version 3.0) is composed of 30 items, embedded in three scales, corresponding to the patient's condition in the past week. The first scale, the Functional Scale, consists of five domains: physical, emotional, social, cognitive, and role functioning. The second scale, the Scale of Symptoms, consists of three sub-scales (pain, fatigue, nausea and vomiting) and six single items (dyspnea, sleep disorders, loss of appetite, constipation, diarrhea, and financial difficulties) and finally, the Global health scale.

Questions 1-28 are answered on a four-point scale, with each item classified from none (score value=1) to very much (score value=4). Questions 29 and 30 are answered on a seven-point scale going from bad (score value=1) to good (score value=7). All items were then linearly transposed onto a scale from 0 to 100. For the five functional scales and global health scale, a higher score indicates a higher level of functioning or overall QoL. Conversely, for the symptom scale and single items, a higher score implies a higher level of symptoms or problems [@b25-cln_72p758].

A second questionnaire associated with the EORTC QLQ-C30, also translated and validated for use in Portuguese, was used to evaluate QoL. This instrument, EORTC BR23, is specifically used for BC patients and consists of 23 questions answered on a 4-point scale (from 1 to 4). It is composed of two scales: the Functional Scale composed of 4 sub-items (body image, sexual function, sexual pleasure and future perspectives) and the Symptom Scale consisting of 4 sub-items (side effects of systemic therapy, breast symptoms, arm symptoms and hair loss) [@b26-cln_72p758]. The use of these questionnaires was authorized both by Ferreira et al. [@b24-cln_72p758] and the EORTC group. All procedures required by the organization were conducted. Additionally, the Karnofsky Performance Status (KPS) was used to evaluate functional capacity.

A descriptive analysis of the qualitative variables was performed through the absolute and relative frequency distribution. The T-test for independent samples was used to compare the mean total scores of the EORTC QLQ-C30 and BR23 variables for pain in the three groups of cancer patients. An analysis of variance (ANOVA) was performed to identify any existing correlations between all collected variables. Then, the Tukey test was applied to evaluate the magnitude of the latter. A significance level of 5% was used, and all calculations were performed using SPSS.V.13.

RESULTS
=======

Evaluating the sociodemographic profile of the 400 women, we see that most women were between 51 to 60 years of age (28.8%) or 41 to 50 (28%), and 60% were from the countryside. Other sociodemographic characteristics show that more than half, or 54.8%, had only received an elementary school education, 51% were married, only 39.3% were on sick leave, and Catholicism predominated in 63.3% of the patients. Concerning clinical variables, 87% of the women had a tumor with the histological appearance of invasive ductal carcinoma, 40% had loco-regional MTX, 76.5% had undergone some prior treatment \[surgery (68.5%), chemotherapy (52.5%), radiation (22.3%), hormonal therapy (29.3%) and/or therapy with bisphosphonates (12.8%)\], and 99% were undergoing some type of treatment \[(surgery\--late post-surgery (4%), chemotherapy (70%), radiotherapy (4%), hormonal therapy (25.3%), and/or therapy with bisphosphonates (19,8%)\] at the time of the interview.

[Table 1](#t1-cln_72p758){ref-type="table"} describes the characteristics of pain, a common complaint among the women (71.7%). Pain was generally reported as diffuse in the three groups of patients. Those who reported pain in more than one site had some form of MTX (36.5% with loco-regional MTX and 45.7% with distant MTX). Interestingly, pain in the upper limbs was more prevalent in patients without MTX.

[Table 1](#t1-cln_72p758){ref-type="table"} also addresses the nature of pain, classifying it according to the frequency of sensory descriptors. For the group without MTX, words such as jumping (70.1%), sore/aching (65.7%) and sharp-pricking (61.2%) were most common. For loco-regional MTX, the subjects described the pain as jumping (80.9%), sore/aching (67.0%) and sharp-pricking (63.5%), whereas patients with distant MTX described it as sore/aching (74.3%), jumping (73.3%) and spreading (66.7%). Within the affective dimension, the most common descriptors for the group without MTX were sickening (61.2%) and nagging (59.7%). The loco-regional MTX group described it as tiring-exhausting (62.6%) and nagging (60.0%); likewise, the distant MTX group preferred words such as tiring-exhausting (80.0%) and nagging (75.2%). In the evaluative dimension, the main descriptor chosen by BC patients was "troublesome" for those without MTX (70.1%), loco-regional MTX (83.5%) and distant MTX (90.5%).

[Table 2](#t2-cln_72p758){ref-type="table"} displays the correlations found between the presence of pain and the different QoL domains (EORTC QLQ-C30 questionnaire): Women who reported pain obtained significantly different scores from those who had no complaints of pain. In the MTX-free group, the mean symptom scores for patients with pain and without pain were 29.0 (SD=15.3) and 13.4 (SD=10.8), respectively (*p*\<0.001). The mean Global Health score for patients with pain was 55.3 (SD=24.8), whereas it was 69.7 (SD=19.2) for those without pain (*p*=0.001). For the loco-regional MTX group, the mean symptom score for patients with pain was 29.0 (SD=15.3), whereas those without pain had an average score of 13.4 (SD=10.8) (*p*\<0.001). On the Global Health Scale, patients in pain scored 59.1 (SD=21.3), and those without pain scored 72.4 (SD=18.6) (*p*\<0.001). For the group with distant MTX, the mean symptom scores for patients with pain and without pain were 39.6 (SD=19.5) and 17.5 (SD=10.0), respectively (*p*\<0.001). On the Global Health Scale, the mean score for those reporting pain was 48.6 (SD=23.1), whereas the mean score for those without pain was 67.6 (SD=20.4) (*p*=0.002). It is important to highlight that the higher the score on the symptom scale, the more symptoms were listed by the patient, thus compromising their QoL.

[Table 2](#t2-cln_72p758){ref-type="table"} also shows us that the presence of pain significantly influences QoL in BC patients when evaluated by EORTC BR23. For patients with distant MTX, those who reported pain had a mean of 56.4 (SD=19.4), whereas those without pain had a mean of 68.4 (SD=13.9) (*p*=0.016). Patients without pain had a better score on self-image evaluation, thus demonstrating how pain can influence self-esteem and how the limbic system influences pain. On the Symptom Scale, the same group of patients obtained a mean of 26.9 (SD=14.2) for those who were in pain and an average of 16.5 (SD=13.8) for those without pain (*p*=0.006).

[Table 3](#t3-cln_72p758){ref-type="table"} not only displays the relationship between pain and QoL but also a possible association between pain intensity and better or worse QoL. Patients with distant MTX who rate their pain as "intense" are those with the worst scores on the QoL assessment, with a mean functional score of 49.9 (SD=17.3) (*p*\<0.009), a mean symptom score of 50.0 (SD=20.1) (*p*\<0.001) and a Global Health Scale mean of 39.7 (SD=24.7) (*p*\<0.006). Functional capacity assessed by the KPS also showed a significant correlation between increased pain intensity and decreased QoL. The latter was observed in all three groups of patients. Women with distant MTX who reported intense pain obtained a mean KPS of 69.0 (SD=13.9) whereas mild pain reports reached a mean KPS of 78.9 (SD=8.7) (*p*\<0.040).

Pain intensity was also evaluated by EORTC BR23, as shown in [Table 4](#t4-cln_72p758){ref-type="table"}. Patients with distant MTX who defined their pain as "intense" scored worse on the Symptom Scale when evaluating QOL, with a mean of 32.1 (SD=14.8) (*p*=0.012). This same association was also observed in the sub-item related to "symptoms of the arm" with a mean of 40.7 (SD=29.4) (*p*=0.001).

DISCUSSION
==========

Pain is one of the most common and distressing symptoms experienced by cancer patients. Cancer pain involves physical, social, psychological and spiritual components, all of which belong to the term "total pain", which is used to refer to the multidimensional nature of pain (Cicely Saunders). The contribution of each component varies based on both individual factors and circumstances faced by the patient. Therefore, the perception of pain is affected by several variables such as fatigue, insomnia, fear, anxiety, anger, sadness, depression, social isolation, altered perception of self-image and impairment of functional capacity [@b27-cln_72p758].

The occurrence of pain may be due to the disease process itself or as treatment aftermath, such as post-mastectomy pain, chemotherapy-induced neuropathy or brachial plexus neuropathy from radiation therapy [@b28-cln_72p758]-[@b30-cln_72p758]. This makes pain a significant problem for most women with BC, causing a negative effect on QoL.

Despite cancer pain having been very prevalent in this study (71.7% of all groups), even in the non-metastatic group (56.8), the heterogeneity of sociodemographic and clinical characteristics of the subjects did not allow a specific statistical additional comparison between groups. This result was similar to that found by Tamai et al. [@b31-cln_72p758], Nabila et al. [@b19-cln_72p758], and Starkweather et al. [@b13-cln_72p758]. Most patients in the sample had distant MTX, which agrees with the literature wherein bone, along with the lungs, is one of the major sites affected by metastatic BC [@b32-cln_72p758],[@b33-cln_72p758]. In a recent cohort study [@b34-cln_72p758], bone was found to be the first site for metastatic development in 41% of the women. Bone MTX are considered the main cause of cancer pain, impairing functional capacity and limiting QoL [@b28-cln_72p758],[@b32-cln_72p758],[@b35-cln_72p758].

The use of descriptors in the evaluation of pain has been increasingly considered pertinent to research and everyday clinical practice. These words help professionals determine type of pain and appropriate therapy to provide patients with the most pain relief and QoL possible [@b36-cln_72p758]. The SF-MPQ showed us that the descriptors most used by the studied population were sore/aching, nagging and troublesome. In agreement with our findings, in a study of 453 Norwegian cancer patients, the most commonly used descriptor for pain was aching [@b36-cln_72p758]. Data obtained from another study found that the most common descriptors were throbbing and tiring-exhausting [@b19-cln_72p758],[@b31-cln_72p758],[@b35-cln_72p758].

When analyzing the association between the presence of pain and the EORTC domains, it was determined that pain negatively influenced QoL. This was true for the patients with and without MTX. The Global Health scale showed that women in pain considered themselves less healthy overall compared to those without pain (*p*=0.002).

The effect of pain on QoL is not only related to the intensity of pain experienced by patients but also to how pain is perceived in its multidimensional aspect [@b16-cln_72p758],[@b17-cln_72p758],[@b37-cln_72p758]. Our findings identified that patients who classified their pain as intense and suffered from MTX had lower mean values on the Global Health Scale. The results clearly show that the group of patients with distant MTX with acute pain was strongly associated with a decrease in QoL.

Pain seemed to impact QoL primarily in patients with distant MTX. These patients not only deal with acute pain but also have significant impairment of the Functional and Symptom Scales. They also suffer from poor body image and are emotionally scarred by the process of treatment and lack of functional capacity. The latter may be because the patient is often disfigured by the palliative treatments made necessary by advanced disease [@b38-cln_72p758].

In addition, the perception of pain may contribute to a warped self-image due to the limbic system's influence on the complexity of pain behavior. Corroborating our findings, a survey of 1965 women with BC conducted in Australia found sexual function to be reduced due to pain and negative body image [@b39-cln_72p758].

Interestingly, among those without MTX, those with pain had lower means than those without for the Future Perspectives item. We believe that this reflects the fact that pain is one of the most feared symptoms, and its presence causes patients worry about its possible cause. This may lead to further worrying about the possibility of MTX and disease progression and consequently one's mortality. The Relationship between QoL and pain seems to be inversely proportional because the higher the pain, the lower the QoL. In accordance with our results, the study by Nesvold et al. [@b40-cln_72p758] identified a significant relationship between the related arm and shoulder problems of women with BC and QoL. It is interesting to note that among those without MTX, those with pain had lower means than those without pain for the Future Perspectives item. We believe that this reflects the fact that pain is one of the most feared symptoms, and its presence causes patients worry about its possible cause. This may lead to further worrying about the possibility of MTX and disease progression and consequently one's mortality.

Despite these interesting findings, the present study should be interpreted with caution in light of its limitations. Pain was evaluated based on self-assessment and included estimates in relation to length of time, without the use of physical parameters. We recognize that some treatments by themselves can highly influence pain and QoL of these patients, and the correlation of these parameters with the results would be desirable; however, the heterogeneity of the used protocols made that impossible. Therefore, the results do not take into account the influence of confounding factors and the sample homogeneity. Further studies using different approaches with longitudinal design may provide better explanations of the complex manifestation of breast cancer.

BC is the most frequent cancer in women worldwide, and pain is one of the most common symptoms, compromising QoL. In this study, pain was highly prevalent and was detected in 71% of the patients. These findings are significant and justify more attention in the management of these patients in daily practice to minimize this unpleasant symptom that damages functional capacity and haunts the patients emotionally.
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###### 

Intensity and dimension of Pain in breast cancer patients.

  Pain                 Breast Cancer Patients                               
  -------------------- ------------------------ ------------- ------------- -------------
  Yes                  67 (56.8)                115 (71.9)    105 (86.1)    287 (71.7)
  No                   51 (43.2)                45 (28.1)     17 (13.9)     113 (28.3)
  Total                118 (100.0)              160 (100.0)   122 (100.0)   400 (100.0)
   Location                                                                 
  Upper limb           19 (28.4)                27 (23.5)     05 (4.8)      51 (17.8)
  Chest                12 (17.9)                20 (17.4)     07 (6.7)      39 (13.6)
  Column               00 (0.0)                 03 (2.6)      09 (8.6)      12 (4.2)
  In two locations     24 (35.8)                42 (36.5)     48 (45.7)     114 (39.7)
  Diffuse              12 (17.9)                23 (20.0)     36 (34.3)     71 (24.7)
  Total                67 (100.0)               115 (100.0)   105 (100.0)   287(100.0)
   Dimension\*                                                              
  **Sensory**                                                               
  Throbbing            34 (50.7)                63 (54.8)     54 (51.4)     151 (52.6)
  Jumping              47 (70.1)                93 (80.9)     77 (73.3)     217 (75.6)
  Flashing             22 (32.8)                34 (29.6)     48 (45.7)     104 (29.8)
  Sharp-pricking       41 (61.2)                73 (63.5)     57 (54.3)     171 (59.6)
  Tugging              36 (53.7)                67 (58.3)     53 (50.5)     156 (54.3)
  Burning              26 (38.8)                44 (38.3)     44 (41.9)     114 (39.7)
  Spreading            27 (40.3)                50 (43.5)     70 (66.7)     147 (51.2)
  Sore/aching          44 (65.7)                77 (67.0)     78 (74.3)     199 (69.3)
  **Affective**                                                             
  Tiring-exhausting    37 (55.2)                72 (62.6)     84 (80.0)     187 (65.1)
  Sickening            41 (61.2)                68 (59.1)     68 (64.8)     177 (61.7)
  Suffocating          14 (20.9)                10 (8.7)      29 (27.6)     53 (18.5)
  Frightful-blinding   14 (20.9)                14 (12.2)     27 (25.7)     55 (19.2)
  Nagging              40 (59.7)                69 (60.0)     79 (75.2)     188 (65.5)
  **Evaluative**                                                            
  Troublesome          47 (70.1)                96 (83.5)     95 (90.5)     238 (82.9)
  Unbearable           06 (9.0)                 14 (12.2)     25 (23.8)     45 (15.7)

Metastasis = MTX \* Counted only for patients with pain.

###### 

Correlation between the presence of Pain and Quality of Life (EORTC QLQC30/BR 23).

  EORTC QLQC30             Presence of pain    *p*-value                 
  ------------------------ ------------------- ----------- ------ ------ -----------
                           Without MTX                                   
  Functional Scales        59.8                19.8        76.9   14.7   \<0.001\*
   Physical functioning    69.9                21.4        84.4   16.0   \<0.001\*
   Role functioning        37.1                32.0        60.4   32.3   \<0.001\*
   Cognitive functioning   65.9                31.8        81.7   20.1   0.001\*
   Emotional functioning   47.0                29.3        65.7   25.6   \<0.001\*
   Social functioning      77.1                32.8        91.8   19.2   0.003\*
  Symptom Scales           29.0                15.3        13.4   10.8   \<0.001\*
  Global Health Scales     55.3                24.8        69.7   19.2   0.001\*
                           Loco-regional MTX                             
  Functional Scales        63.9                17.5        74.7   15.4   \<0.001\*
   Physical functioning    69.7                21.4        78.5   22.4   0.023\*
   Role functioning        38.8                30.1        53.7   34.2   0.008\*
   Cognitive functioning   75.5                26.1        83.0   19.9   0.055
   Emotional functioning   55.6                29.1        68.5   25.4   0.010\*
   Social functioning      79.8                28.7        89.2   18.8   0.017\*
  Symptom Scales           29.0                15.3        13.4   10.8   \<0.001\*
  Global Health Scales     59.1                21.3        72.4   18.6   \<0.001\*
                           Distant MTX                                   
  Functional Scales        54.1                17.4        73.1   17.5   \<0.001\*
   Physical functioning    54.0                27.4        74.5   23.9   0.004\*
   Role functioning        27.1                31.3        53.9   36.1   0.002\*
   Cognitive functioning   70.5                30.2        79.4   23.9   0.249
   Emotional functioning   47.9                27.7        70.1   29.0   0.003\*
   Social functioning      77.1                29.6        88.2   20.2   0.061
  Symptom Scales           39.6                19.5        17.5   10.0   \<0.001\*
  Global Health Scales     48.6                23.1        67.6   20.4   0.002\*
  **EORTC BR23**                                                         
                           Without MTX                                   
  Functional Scales        56.6                20.2        67.8   15.7   0.001\*
   Body image              68.8                30.9        84.3   22.1   0.002\*
   Sexual functioning      26.1                27.9        27.8   28.8   0.753
   Sexual enjoyment        51.0                32.8        58.7   31.4   0.400
   Future perspective      31.3                37.1        47.1   39.5   0.029\*
  Symptom Scales           30.9                18.5        13.0   13.0   \<0.001\*
                           Loco-regional MTX                             
  Functional Scales        61.1                17.4        71.0   12.0   \<0.001\*
   Body image              73.5                27.5        87.0   17.4   \<0.001\*
   Sexual functioning      29.1                29.5        21.8   28.6   0.159
   Sexual enjoyment        59.0                35.4        56.4   28.5   0.812
   Future perspective      39.7                39.5        65.2   41.0   \<0.001\*
  Symptom Scales           29.0                15.3        13.4   10.8   \<0.001\*
                           Distant MTX                                   
  Functional Scales        56.4                19.4        68.4   13.9   0.016\*
   Body image              68.2                32.7        86.3   18.8   0.003\*
   Sexual functioning      23.8                26.0        26.5   27.0   0.697
   Sexual enjoyment        47.9                30.6        62.5   21.4   0.203
   Future perspective      36.2                39.3        49.0   33.6   0.205
  Symptom Scales           26.9                14.2        16.5   13.8   0.006\*

Metastasis = MTX \* T-test.

###### 

Correlation between the level of Pain, Quality of Life and Functional capacity.

  EORTC QLQ30/KPS          Intensity of pain   *p*-value                                  
  ------------------------ ------------------- ----------- -------- ------ ------- ------ -----------
                           Without MTX                                                    
  Functional Scales        69.3a               16.6        54.0b    18.6   50.3b   22.0   0.003\*
   Physical functioning    81.2a               13.7        64.0b    23.4   56.4b   19.8   \<0.001\*
   Role functioning        43.8                29.3        32.1     32.7   33.3    36.5   0.370
   Cognitive functioning   73.2                30.9        58.9     31.2   65.1    34.5   0.246
   Emotional functioning   58.9a               31.2        40.2b    25.7   34.1b   23.7   0.014\*
   Social functioning      83.3                29.0        73.8     35.3   69.7    35.6   0.402
  Symptom Scales           22.1a               15.2        30.3ab   16.8   39.4b   15.1   0.009\*
  Global Health Scales     60.1                21.8        51.8     24.1   52.3    32.9   0.416
  KPS                      92.9a               6.6         86.1b    10.7   80.0b   13.4   0.001\*
                           Loco-regional MTX                                              
  Functional Scales        24.1                13.3        73.6     14.5   38.2    14.8   0.321
   Physical functioning    73.6                22.1        67.5     21.1   66.7    21.1   0.295
   Role functioning        40.2                30.3        41.7     32.5   30.3    21.8   0.249
   Cognitive functioning   74.0                27.4        80.1     23.7   70.2    27.7   0.264
   Emotional functioning   57.9                28.9        58.3     28.2   47.3    29.7   0.228
   Social functioning      80.5                27.9        75.7     31.0   85.7    25.9   0.347
  Symptom Scales           27.5a               13.9        33.6ab   14.3   23.5b   16.8   0.015\*
  Global Health Scales     59.3                20.8        60.1     21.9   55.9    20.3   0.698
  KPS                      88.5a               7.3         87.4a    9.7    82.5b   8.8    0.013\*
                           Distant MTX                                                    
  Functional Scales        61.7a               15.4        56.1ab   16.8   47.9b   17.3   0.009\*
   Physical functioning    65.6a               22.7        56.3ab   26.1   45.6b   29.0   0.024\*
   Role functioning        39.5                33.9        56.3     26.1   19.2    28.0   0.061
   Cognitive functioning   76.3                25.0        65.6     32.7   73.5    29.3   0.317
   Emotional functioning   53.5                31.2        52.8     25.5   39.3    26.9   0.048
   Social functioning      76.3                30.1        80.1     24.7   73.9    34.8   0.625
  Symptom Scales           23.6a               10.5        37.5b    16.8   50.0c   20.1   \<0.001\*
  Global Health Scales     50.0a               20.2        55.5ab   20.6   39.7b   24.7   0.006\*
  KPS                      78.9a               8.7         75.5a    69.0   69.0b   13.9   0.040\*

Metastasis = MTX \* ANOVA - test.

Tukey test - the means of the different letters are statistically significant.

###### 

Correlation between the level of Pain and Quality of Life in breast cancer women.

  EORTC BR23                      Intensity of pain   *p*-value                                 
  ------------------------------- ------------------- ----------- ------- ------ ------- ------ -----------
                                  Without MTX                                                   
  Symptom Scales                  26.1                17.7        33.2    17.8   37.6    20.6   0.154
  Systemic therapy side effects   30.3                24.1        35.9    25.9   39.8    21.8   0.495
  Breast symptoms                 32.4                18.3        34.8    20.8   32.6    29.9   0.908
  Arm symptoms                    14.7a               18.4        31.7a   25.4   45.5b   21.3   \<0.001\*
  Upset by hair loss              5.9                 43.6        11.9    53.4   18.2    58.4   0.779
                                  Loco-regional MTX                                             
  Symptom Scales                  30.7                14.8        32.3    15.0   26.3    13.5   0.225
  Systemic therapy side effects   31.0                18.4        38.0    23.4   26.5    21.0   0.073
  Breast symptoms                 39.0                20.2        30.8    19.5   32.1    19.2   0.145
  Arm symptoms                    27.0                20.0        26.1    19.8   26.0    19.6   0.974
  Upset by hair loss              12.2                22.1        12.3    25.7   7.1     18.9   0.591
                                  Distant MTX                                                   
  Symptom Scales                  22.6a               10.8        24.3b   13.8   32.1b   14.8   0.012\*
  Systemic therapy side effects   24.8                14.5        27.9    19.9   36.1    18.5   0.046
  Breast symptoms                 27.2                14.4        27.7    19.2   29.1    27.4   0.939
  Arm symptoms                    22.2a               22.2        21.7b   17.9   40.7b   29.4   0.001\*
  Upset by hair loss              10.5                31.5        7.1     42.2   10.3    42.7   0.920

Metastasis = MTX \* ANOVA -test.

Tukey test - the means of the different letters are statistically significant.
